Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells 1,000 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lantheus Stock Performance

Shares of Lantheus stock opened at $91.47 on Friday. The firm has a 50-day moving average of $89.72 and a 200-day moving average of $99.85. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market cap of $6.36 billion, a PE ratio of 15.22 and a beta of 0.46.

Analyst Ratings Changes

A number of research analysts recently weighed in on LNTH shares. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. Truist Financial restated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the third quarter worth approximately $25,000. Signaturefd LLC grew its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. increased its stake in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the period. Kathleen S. Wright Associates Inc. bought a new position in Lantheus during the 3rd quarter worth $51,000. Finally, GAMMA Investing LLC raised its holdings in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.